Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen
https://diffusionpharma.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
150
150
Diffusion Pharmaceuticals Inc.
https://diffusionpharma.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.